Patents by Inventor Toby Jonathan Blench
Toby Jonathan Blench has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240016941Abstract: The invention provides a combinations and pharmaceutical compositions comprising (i) a compound which is an indane according to Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) one or more CFTR modulator; wherein R1, R2, R3, R4, n, Lk, (A), G and m are as defined herein. Also provided are therapeutic uses of such combinations and compositions in the treatment of conditions such as cystic fibrosis.Type: ApplicationFiled: March 23, 2021Publication date: January 18, 2024Applicant: Antabio SASInventors: Martin Everett, Simon Leiris, David Thomas Davies, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
-
Publication number: 20230139502Abstract: The invention provides aza-heterocyclyl carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxC activity.Type: ApplicationFiled: April 27, 2022Publication date: May 4, 2023Inventors: Michael Dominic Ryan, Thomas David Pallin, Toby Jonathan Blench, Toby Matthew Grover Mullins, David Edward Clark, Emanuela Gancia, Nadia Mamoona Ahmad
-
Publication number: 20220112169Abstract: The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, n and p are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.Type: ApplicationFiled: July 25, 2019Publication date: April 14, 2022Applicant: Antabio SASInventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
-
Publication number: 20210347748Abstract: The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, n and p are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.Type: ApplicationFiled: July 25, 2019Publication date: November 11, 2021Applicant: Antabio SASInventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
-
Patent number: 11000511Abstract: The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.Type: GrantFiled: March 21, 2018Date of Patent: May 11, 2021Assignee: Antabio SASInventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Jonathan Mark Sutton, Michael Steven Bodnarchuk, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, David Edward Clark, Richard Leonard Elliott, Lilha Beyria
-
Publication number: 20200155509Abstract: The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p, q, L, X and m are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics. The compounds can also be used in vitro, for example in cleaning compositions.Type: ApplicationFiled: March 21, 2018Publication date: May 21, 2020Applicant: Antabio SASInventors: Simon LEIRIS, David Thomas DAVIES, Martin EVERETT, Nicolas SPRYNSKI, Jonathan Mark SUTTON, Michael Steven BODNARCHUK, Thomas David PALLIN, Andrew Peter CRIDLAND, Toby Jonathan BLENCH, David Edward CLARK, Richard Leonard ELLIOTT, Lilha BEYRIA
-
Patent number: 9023855Abstract: Compounds of formula (I): are useful as inhibitors of human neutrophil elastase.Type: GrantFiled: February 11, 2014Date of Patent: May 5, 2015Assignee: Chiesi Farmaceutici S.p.A.Inventors: Toby Jonathan Blench, Christine Edwards, Robert Andrew Heald, Janusz Jozef Kulagowski, Jonathan Mark Sutton, Carmelida Capaldi
-
Publication number: 20140179714Abstract: Compounds of formula (I): are useful as inhibitors of human neutrophil elastase.Type: ApplicationFiled: February 11, 2014Publication date: June 26, 2014Applicant: Chiesi Farmaceutici S.p.A.Inventors: Toby Jonathan Blench, Christine Edwards, Robert Andrew Heald, Janusz Jozef Kulagowski, Jonathan Mark Sutton, Carmelida Capaldi
-
Publication number: 20140171408Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.Type: ApplicationFiled: February 20, 2014Publication date: June 19, 2014Applicant: Genentech, Inc.Inventors: Toby Jonathan Blench, Charles Ellwood, Simon Charles Goodacre, Yingjie Lai, Jun Liang, Calum MacLeod, Steven R. Magnuson, Vickie Hsiao-Wei Tsui, Karen Williams, Birong Zhang
-
Patent number: 8697708Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.Type: GrantFiled: September 14, 2011Date of Patent: April 15, 2014Assignee: F. Hoffmann-La Roche AGInventors: Toby Jonathan Blench, Charles Ellwood, Simon Charles Goodacre, Yingjie Lai, Jun Liang, Calum Macleod, Steven R. Magnuson, Vickie H. Tsui, Karen Williams, Birong Zhang
-
Patent number: 8691826Abstract: Compounds of formula (I): are useful as inhibitors of human neutrophil elastase.Type: GrantFiled: September 13, 2012Date of Patent: April 8, 2014Assignee: Chiesi Farmaceutici S.p.A.Inventors: Toby Jonathan Blench, Christine Edwards, Robert Andrew Heald, Janusz Jozef Kulagowski, Jonathan Mark Sutton, Carmelida Capaldi
-
Patent number: 8546376Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.Type: GrantFiled: September 17, 2010Date of Patent: October 1, 2013Assignee: Almac Discovery LimitedInventors: Mark Peter Bell, Timothy Harrison, Sumita Bhattacharyya, James Samuel Shane Rountree, Frank Burkamp, Stephen Price, Calum MacLeod, Richard Leonard Elliott, Phillip Smith, Toby Jonathan Blench, Colin Roderick O'Dowd, Lixin Zhang, Graham Peter Trevitt, Hazel Joan Dyke
-
Publication number: 20130065913Abstract: Compounds of formula (I): are useful as inhibitors of human neutrophil elastase.Type: ApplicationFiled: September 13, 2012Publication date: March 14, 2013Applicant: Chiesi Farmaceutici S.p.A.Inventors: Toby Jonathan Blench, Christine Edwards, Robert Andrew Heald, Janusz Jozef Kulagowski, Jonathan Mark Sutton, Carmelida Capaldi
-
Publication number: 20120238541Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.Type: ApplicationFiled: September 17, 2010Publication date: September 20, 2012Applicant: Almac Discovery LimitedInventors: Mark Peter Bell, Timothy Harrison, Sumita Bhattacharyya, James Samuel Shane Rountree, Frank Burkamp, Stephen Price, Calum MacLeod, Richard Leonard Elliott, Phillip Smith, Toby Jonathan Blench, Colin Roderick O'Dowd, Lixin Zhang, Graham Peter Trevitt, Hazel Joan Dyke
-
Publication number: 20120202788Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.Type: ApplicationFiled: September 14, 2011Publication date: August 9, 2012Inventors: Toby Jonathan Blench, Charles Ellwood, Simon Charles Goodacre, Yingjie Lai, Jun Liang, Calum Macleod, Steven R. Magnuson, Vickie H. Tsui, Karen Williams, Birong Zhang
-
Patent number: 8168633Abstract: Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: GrantFiled: January 7, 2011Date of Patent: May 1, 2012Assignee: Genentech, Inc.Inventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Jahusz Jozef Kulagowski, Alan John Nadin, Stephen Price
-
Publication number: 20110098270Abstract: Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: January 7, 2011Publication date: April 28, 2011Inventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Jahusz Jozef Kulagowski, Alan John Nadin, Stephen Price
-
Patent number: 7893060Abstract: Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R3 is H or C1-C6 alkyl; and R4 is an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: GrantFiled: June 12, 2008Date of Patent: February 22, 2011Assignee: F. Hoffmann-La Roche AGInventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Janusz Jozef Kulagowski, Alan John Nadin, Stephen Price
-
Publication number: 20100190769Abstract: Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R is H or C1-C6 alkyl; and R is an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: June 12, 2008Publication date: July 29, 2010Inventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Janusz Jozef Kulagowski, Alan John Nadin, Stephen Price
-
Publication number: 20090221564Abstract: Heterocyclic compounds of the formula (I) are provided: wherein ring A, ring B, R1, R2, R3, R4, Y, m, n and q are as identified herein. R1 is in particular amidino. The invention further provides particular benzothiophene compounds. Compounds of the invention may be useful as inhibitors of Factor IXa and in the therapy of cardiovascular conditions and diseases, e.g. thrombosis.Type: ApplicationFiled: February 20, 2007Publication date: September 3, 2009Applicant: TRIGEN LIMITEDInventors: Shouming Wang, Toby Jonathan Blench, Frederic Marlin, Richard Beck, Roger Peter Dickinson